Advanced Biomed (NASDAQ:ADVB) Issues Earnings Results

Posted by on May 16th, 2026

Advanced Biomed (NASDAQ:ADVB – Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.38) EPS for the quarter, Zacks reports.

Advanced Biomed Stock Performance

Shares of ADVB traded down $0.03 during trading hours on Friday, hitting $4.40. The company had a trading volume of 13,563 shares, compared to its average volume of 328,908. The stock has a market capitalization of $5.98 million, a price-to-earnings ratio of 1.16 and a beta of 0.56. The stock has a fifty day moving average price of $5.19. Advanced Biomed has a 12 month low of $3.61 and a 12 month high of $25.60.

Analyst Ratings Changes

Separately, Weiss Ratings began coverage on shares of Advanced Biomed in a research report on Monday, January 26th. They issued a “sell (e+)” rating on the stock. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Check Out Our Latest Analysis on ADVB

Advanced Biomed Company Profile

(Get Free Report)

Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.

Read More

Receive News & Ratings for Advanced Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Biomed and related companies with MarketBeat.com's FREE daily email newsletter.